Table 1.
Clinical data input from the COMPASS trial
| Parameter | CAD or PAD | PAD | CAD | CAD and PAD | CAD with CKD | CAD with HF |
|---|---|---|---|---|---|---|
| Age, years [mean (range)] | 68.24 (60–75) | 67.81 (60–75) | 68.34 (60–75) | 68.06 (60–75) | 71.74 (65–79) | 65.49 (58–72) |
| Sex, male [n (%)] |
21,375/27,395 (78.0) |
5361/7470 (71.8) |
19,792/24,824 (79.7) |
3782/4906 (77.1) |
3038/5561 (70.8) |
4418/5714 (77.3) |
| Clinical inputs | ||||||
| Risk of acute main events (fatal and non-fatal, ASA arm), 3-month probability | ||||||
| MI | 0.00290 | 0.00357 | 0.00301 | 0.00448 | 0.00483 | 0.00361 |
| IS | 0.00176 | 0.00225 | 0.00174 | 0.00236 | 0.00256 | 0.00250 |
| ICH | 0.00029 | 0.00049 | 0.00030 | 0.00065 | 0.00043 | 0.00015 |
| ALI | 0.00064 | 0.00221 | 0.00043 | 0.00191 | 0.00069 | 0.00072 |
| VTE | 0.00061 | 0.00092 | 0.00062 | 0.00111 | 0.00104 | 0.00072 |
| Major extracranial bleed | 0.00217 | 0.00226 | 0.00219 | 0.00239 | 0.00367 | 0.00239 |
| Minor amputation | 0.00043 | 0.00135 | 0.00026 | 0.00096 | 0.00055 | 0.00036 |
| Major amputation | 0.00037 | 0.00124 | 0.00019 | 0.00072 | 0.00041 | 0.00029 |
| RIV + ASA treatment efficacy in terms of events (relative to ASA alone) | ||||||
| HR (95% CI) | ||||||
| MI | 0.86 (0.70–1.05) | |||||
| IS | 0.51 (0.38–0.69) | |||||
| ICH | 1.16 (0.67–2.00) | |||||
| ALI | 0.55 (0.32–0.93) | |||||
| VTE | 0.61 (0.37–1.00) | |||||
| Major extracranial bleed | 1.79 (1.46–2.19) | |||||
| Minor amputation | 0.65 (0.35–1.20) | |||||
| Major amputation | 0.57 (0.30–1.09) | |||||
| Utility weight of events (0–3 months), mean | ||||||
| MI | 0.7840 | 0.7390 | 0.7910 | 0.7470 | 0.7630 | 0.7510 |
| IS | 0.6470 | 0.6100 | 0.6520 | 0.6170 | 0.6300 | 0.6200 |
| ICH | 0.7020 | 0.6620 | 0.7080 | 0.6690 | 0.6840 | 0.6730 |
| Utility decrements for health events | ||||||
| ALI | − 0.157 | |||||
| VTE | − 0.111 | |||||
| Major extracranial bleed | − 0.019 | |||||
| Minor amputation | − 0.100 | |||||
| Major amputation | − 0.175 | |||||
Data inputs are derived from the COMPASS trial [7]
CAD coronary artery disease, PAD peripheral artery disease, CKD chronic kidney disease, HF heart failure, RIV rivaroxaban, ASA aspirin, MI myocardial infarction, IS ischemic stroke, ICH intracranial hemorrhage, HR hazard ratio, CI confidence interval, ALI acute limb ischemia, VTE venous thromboembolism